# A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

> **NCT05039736** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05039736
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-24
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participants accrued
- **Last updated:** 2023-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039736, "A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05039736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*